TNDM - Tandem Diabetes Care, Inc.
| Previous Close | 61.31 |
| Open | 61.40 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 1300 |
| Day's Range | 61.10 - 63.13 |
| 52 Week Range | 26.40 - 74.81 |
| Volume | 974,326 |
| Avg. Volume | 1,361,878 |
| Market Cap | 3.7B |
| Beta (3Y Monthly) | -0.13 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.96 |
| Earnings Date | Oct 30, 2019 - Nov 4, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 82.38 |
- Zacks
Zacks.com featured highlights include: Crocs, Skechers, Tandem, CyberArk and Fortinet
Zacks.com featured highlights include: Crocs, Skechers, Tandem, CyberArk and Fortinet
- Zacks
Tandem Diabetes Rides on t:slim X2 Uptake, Product Pipeline
Robust domestic sales along with a strong unveiling of the t:slim X2 Insulin Pump in the international markets augur well for Tandem Diabetes (TNDM).
- Motley Fool
3 Top Diabetes Stocks to Watch in August
These three diabetes-oriented companies should be on your radar right now.
- Zacks
Beyond Earnings Growth: Focus on Beat With These 5 Stocks
Inside the top-ranked stocks that can beat earnings estimates in their next release.
- Thomson Reuters StreetEvents
Edited Transcript of TNDM earnings conference call or presentation 30-Apr-19 8:30pm GMT
Q1 2019 Tandem Diabetes Care Inc Earnings Call
- GuruFocus.com
Tandem Diabetes Care Inc (TNDM) EVP & CHIEF COMMERCIAL OFFICER Brian B Hansen Sold $944,550 ...
EVP & CHIEF COMMERCIAL OFFICER of Tandem Diabetes Care Inc (30-Year Financial, Insider Trades) Brian B Hansen (insider trades) sold 15,000 shares of TNDM on 08/12/2019 at an average price of $62.97 a share. Continue reading...
- Zacks
Tandem (TNDM) Q2 Loss Narrower Than Expected, Sales Top Mark
Tandem Diabetes' (TNDM) t:slim X2 Insulin pump's strength in domestic sales along with expansion in international markets during Q2 is encouraging.
- TheStreet.com
The Charts of Tandem Diabetes Are Probably Headed Higher With This Subtle Clue
In his final "Executive Decision" segment of Mad Money Wednesday night, Jim Cramer also checked in with Kim Blickenstaff, executive chairman at Tandem Diabetes Care , which posted strong earnings last week that sent shares up over 8% before giving back much of those gains by the close. Blickenstaff blamed the sudden reversal in their shares on global uncertainty. Currently, only 30% of Type 1 diabetes patients are using a pump, Blickenstaff said, leaving a lot of room for growth for Tandem.
- Zacks
Zacks.com featured highlights include: Crocs, IAC/InterActive, Fortinet, Tandem Diabetes and Cross Country
Zacks.com featured highlights include: Crocs, IAC/InterActive, Fortinet, Tandem Diabetes and Cross Country
- Motley Fool
Tandem Diabetes Care Raises Full-Year 2019 Revenue Guidance to $358 Million
The medical device company got oh-so-close to erasing operating losses in Q2, but second-half growth will finally put the business in the black.
- Zacks
5 Top-Ranked Stocks Primed for an Earnings Beat
Inside the top-ranked stocks that can beat earnings estimates in their next releases.
- Simply Wall St.
Is There An Opportunity With Tandem Diabetes Care, Inc.'s (NASDAQ:TNDM) 47% Undervaluation?
Today we will run through one way of estimating the intrinsic value of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) by...
Motley FoolTandem Diabetes Care Inc (TNDM) Q2 2019 Earnings Call Transcript
TNDM earnings call for the period ending June 30, 2019.
Motley FoolTandem Diabetes Care Pumps Up Sales Dramatically in Q2
The insulin pump maker trounced analysts' top- and bottom-line estimates on strong sales growth.
- Business Wire
Tandem Diabetes Care Announces Second Quarter 2019 Financial Results and Updated 2019 Financial Guidance
Tandem Diabetes Care, Inc. , a leading insulin delivery and diabetes technology company, today reported its financial results for the quarter ended June 30, 2019 and updated its financial guidance for the year ending December 31, 2019.
- Business Wire
Tandem Diabetes Care Announces No-Cost Software Updates for t:slim X2 Insulin Pump Customers in the United States
Tandem Diabetes Care, Inc. (TNDM), a leading insulin delivery and diabetes technology company, today announced it is offering no-cost feature updates for t:slim X2 insulin pump customers in the United States through the end of 2020. “Our ability to provide our customers with remote feature updates exemplifies our Company’s mission to improve the lives of people with diabetes through relentless innovation and revolutionary customer experience,” said John Sheridan, president and CEO of Tandem Diabetes Care.
- Zacks
The Zacks Analyst Blog Highlights: Repligen, Tandem Diabetes Care, Telephone and Data Systems, Sunoco and Rent-A-Center
The Zacks Analyst Blog Highlights: Repligen, Tandem Diabetes Care, Telephone and Data Systems, Sunoco and Rent-A-Center
- Zacks
5 Top Picks on Three Key Takeaways From Q2 U.S. GDP
A closer look at the second-quarter GDP will help us to make three important inferences, which are expected to give guidance on the economy and stock market in the near term.
- Zacks
Can IDEXX's (IDXX) International Growth Drive Q2 Earnings?
In the United States, IDEXX (IDXX) witnesses a strong uptrend in CAG Diagnostic recurring revenues.
- Zacks
Tandem Diabetes (TNDM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Tandem Diabetes (TNDM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Business Wire
Tandem Diabetes Care to Announce Second Quarter 2019 Financial Results on August 1, 2019
Tandem Diabetes Care, Inc. , a leading insulin delivery and diabetes technology company, plans to release its second quarter 2019 results after the financial markets close on Thursday, August 1, 2019.
- Motley Fool
3 Top Diabetes Stocks to Watch in July
These three medtech companies are at the forefront of diabetes care.
- GuruFocus.com
Tandem Diabetes Care Inc (TNDM) EVP & CHIEF COMMERCIAL OFFICER Brian B Hansen Sold $912,691 ...
EVP & CHIEF COMMERCIAL OFFICER of Tandem Diabetes Care Inc (TNDM) Brian B Hansen (insider trades) sold 13,031 shares of TNDM on 07/11/2019 at an average price of $70.04 a share. Continue reading...
- Simply Wall St.
When Can We Expect A Profit From Tandem Diabetes Care, Inc. (NASDAQ:TNDM)?
Tandem Diabetes Care, Inc.'s (NASDAQ:TNDM): Tandem Diabetes Care, Inc., a medical device company, designs, develops...
- Business Wire
Tandem Diabetes Care Announces Upcoming Conference Presentation
Tandem Diabetes Care, Inc. , a leading insulin delivery and diabetes technology company, today announced that John Sheridan, president and chief executive officer, will present at the BMO 2019 Prescriptions for Success Healthcare Conference on Tuesday, June 25, 2019 in New York at 1:20pm Eastern Time .
